急性虚血性脳卒中市場 - 市場の洞察、疫学、市場予測：2034年

急性虚血性脳卒中の市場規模は、2023年では主要7ヶ国の中で米国が最も大きく、約8億100万米ドルを占め、2034年までにCAGR 11％でさらに拡大すると予測されています。2023年に急性虚血性脳卒中と診断済み症例数は、主要7ヶ国の中で米国が最も多く、約75万4,000件で、2034年までにさらに増加すると予測されています。米国では、2023年に男性37万6,000人、女性37万8,000人が急性虚血性脳卒中に罹患しました。

急性虚血性脳卒中市場を牽引しているのは、血栓除去術の進歩、ライフスタイル要因による罹患率の上昇、脳卒中治療への資金援助です。障壁としては、限られた治療期間、高額な費用、認知度の低さなどが挙げられます。アンメットニーズには、診断の改善、治療期間の延長、神経保護、脳卒中後のリハビリテーションの改善などが含まれます。

現在の急性虚血性脳卒中治療市場は、抗血小板薬、抗凝固薬、組織プラスミノーゲン活性化薬（tPA）、エダラボン、脂質低下薬で構成されています。しかし、この市場は、治療の幅の狭さ、診断の遅れ、専門的治療へのアクセスの制限、安全性への懸念、高コスト、規制上の障害など、大きな課題に直面しています。これらの問題は、早期発見の改善、社会教育、より効果的で利用しやすい治療法の必要性を浮き彫りにしています。

急性虚血性脳卒中（Acute Ischemic Stroke：AIS）は、脳に血液を供給する血管が閉塞し、血流が低下して酸素が欠乏することで発症します。この閉塞は一般的に血栓によって引き起こされ、狭窄した動脈（アテローム性動脈硬化症）で形成されたり、心臓や体内の他の場所から移動したりすることが多いです。その結果、酸素と栄養素が不足し、脳細胞が死滅し、麻痺、言語障害、認知障害などの神経障害が生じます。血流を回復させ、脳の損傷を最小限に抑えるためには、静脈内血栓溶解療法や機械的血栓除去術などの早急な医療介入が重要です。AISの危険因子には、高血圧、糖尿病、喫煙、肥満などがあります。

急性虚血性脳卒中の診断には、臨床評価と画像診断の組み合わせが必要です。患者はしばしば、脱力、言語障害、視覚障害などの突然の神経症状を呈します。NIH脳卒中スケール（NIHSS）を用いた迅速な評価は、脳卒中の重症度の判定に役立ちます。コンピュータ断層撮影（CT）検査や磁気共鳴画像（MRI）検査は、虚血性脳卒中と出血性脳卒中を鑑別し、罹患した脳部位や虚血の有無を特定するために極めて重要です。さらに、CT血管造影やMR血管造影のような血管画像技術は、血管の閉塞を評価し、適切な治療戦略を導くために使用されます。

急性虚血性脳卒中（AIS）の治療は、脳の患部への血流を速やかに回復させることに重点を置く。主な治療法は、血栓を溶解する組織プラスミノーゲンアクチベーター（tPA）による血栓溶解療法で、症状発現から4.5時間以内の投与が最も効果的です。機械的血栓除去術は、特殊な器具を用いて血栓を物理的に除去する治療法で、特に脳卒中発症から24時間以内に施行される場合に有効です。早期診断と迅速な治療は、脳障害を最小限に抑え、回復の転帰を改善する上で極めて重要です。その他の治療としては、抗血小板薬、抗凝固薬、脳卒中治療室での支持療法などがあります。

当レポートでは、主要7ヶ国における急性虚血性脳卒中市場について調査し、市場の概要とともに、疫学、患者動向、新たな治療法、2034年までの市場規模予測、および医療のアンメットニーズなどを提供しています。

目次

第1章 重要な洞察

第2章 レポートのイントロダクション

第3章 急性虚血性脳卒中市場概要

第4章 疫学と市場予測の調査手法

第5章 重要な出来事

第6章 エグゼクティブサマリー

第7章 疾患の背景と概要

• イントロダクション
• 兆候と症状
• 急性虚血性脳卒中の段階と臨床症状
• 原因
• 病因
• 急性虚血性脳卒中の診断
• 鑑別診断
• 治療と管理

第8章 急性虚血性脳卒中の疫学と患者人口

• 主な調査結果：疫学
• 前提と根拠：主要7ヶ国
• 主要7ヶ国における急性虚血性脳卒中の発症例数
• 主要7ヶ国における急性虚血性脳卒中の診断済み症例総数
• 米国
• EU4ヶ国と英国
• 日本

第9章 急性虚血性脳卒中の患者動向

第10章 急性虚血性脳卒中の上市済み薬剤

第11章 新興薬剤

第12章 急性虚血性脳卒中市場：主要7ヶ国市場分析

• 主な調査結果
• 主要な市場予測の前提条件
• 急性虚血性脳卒中市場の見通し
• 主要7ヶ国における急性虚血性脳卒中の総市場規模
• 主要7ヶ国における急性虚血性脳卒中の治療薬市場規模
• 米国
• EU4ヶ国と英国
• 日本

第13章 主要オピニオンリーダーの見解

第14章 急性虚血性脳卒中のSWOT分析

第15章 急性虚血性アンメットニーズ

第16章 急性虚血性脳卒中市場アクセスと償還

• 米国
• EU4ヶ国と英国
• 日本

第17章 付録

第18章 レポートの調査手法

第19章 DelveInsightのサービス内容

第20章 免責事項

List of Tables

• Table 1 Summary of Acute Ischemic Stroke Market and Epidemiology (2020-2034)
• Table 2 Causes and locations of Acute Ischemic Stroke
• Table 3 Etiopathogenesis of Acute Ischemic Stroke
• Table 4 Total Incident Cases of Acute Ischemic Stroke In the 7MM (2020-2034)
• Table 5 Total Diagnosed Incident Cases of Acute Ischemic Stroke In the 7MM (2020-2034)
• Table 6 Total Diagnosed Incident Cases of Acute Ischemic Stroke in the US (2020-2034)
• Table 7 Age-specific cases of Acute Ischemic Stroke in the US (2020-2034)
• Table 8 Gender-specific Cases of Acute Ischemic Stroke in the US (2020-2034)
• Table 9 Type-specific cases of Acute Ischemic Stroke in the US (2020-2034)
• Table 10 Total Diagnosed Incident Cases of Acute Ischemic Stroke in Germany (2020-2034)
• Table 11 Total Diagnosed Incident Cases of Acute Ischemic Stroke in France (2020-2034)
• Table 12 Total Diagnosed Incident Cases of Acute Ischemic Stroke in Italy (2020-2034)
• Table 13 Total Diagnosed Incident Cases of Acute Ischemic Stroke in Spain (2020-2034)
• Table 14 Total Diagnosed Incident Cases of Acute Ischemic Stroke in the UK (2020-2034)
• Table 15 Total Diagnosed Incident Cases of Acute Ischemic Stroke in EU4 and the UK (2020-2034)
• Table 16 Age-specific cases of Acute Ischemic Stroke in Germany (2020-2034)
• Table 17 Age-specific cases of Acute Ischemic Stroke in France (2020-2034)
• Table 18 Age-specific cases of Acute Ischemic Stroke in Italy (2020-2034)
• Table 19 Age-specific cases of Acute Ischemic Stroke in Spain (2020-2034)
• Table 20 Age-specific cases of Acute Ischemic Stroke in the UK (2020-2034)
• Table 21 Age-specific cases of Acute Ischemic Stroke in EU4 and the UK (2020-2034)
• Table 22 Gender-specific Cases of Acute Ischemic Stroke in Germany (2020-2034)
• Table 23 Gender-specific Cases of Acute Ischemic Stroke in France (2020-2034)
• Table 24 Gender-specific Cases of Acute Ischemic Stroke in Italy (2020-2034)
• Table 25 Gender-specific cases of Acute Ischemic Stroke in Spain (2020-2034)
• Table 26 Gender-specific Cases of Acute Ischemic Stroke in the UK (2020-2034)
• Table 27 Gender-specific Cases of Acute Ischemic Stroke in EU4 and the UK (2020-2034)
• Table 28 Type-specific cases of Acute Ischemic Stroke in Germany (2020-2034)
• Table 29 Type-specific cases of Acute Ischemic Stroke in France (2020-2034)
• Table 30 Type-specific cases of Acute Ischemic Stroke in Italy (2020-2034)
• Table 31 Type-specific cases of Acute Ischemic Stroke in Spain (2020-2034)
• Table 32 Type-specific cases of Acute Ischemic Stroke in the UK (2020-2034)
• Table 33 Type-specific cases of Acute Ischemic Stroke in EU4 and the UK (2020-2034)
• Table 34 Total Diagnosed Incident Cases of Acute Ischemic Stroke in Japan (2020-2034)
• Table 35 Age-specific cases of Acute Ischemic Stroke in Japan (2020-2034)
• Table 36 Gender-specific Cases of Acute Ischemic Stroke in Japan (2020-2034)
• Table 37 Type-specific cases of Acute Ischemic Stroke in Japan (2020-2034)
• Table 38 Comparison of Emerging Drugs
• Table 39 Glenzocimab (ACT017), Clinical Trial Description, 2024
• Table 40 LT3001, Clinical Trial Description, 2024
• Table 41 DM199, Clinical Trial Description, 2024
• Table 42 Acute Ischemic Stroke Market Size by Therapies in the 7MM, USD million (2020-2034)
• Table 43 Total Acute Ischemic Stroke Market Size in the US, in USD million (2020-2034)
• Table 44 Acute Ischemic Stroke Market Size by Therapies in the US, USD million (2020-2034)
• Table 45 Total Acute Ischemic Stroke Market Size in Germany, in USD million (2020-2034)
• Table 46 Total Acute Ischemic Stroke Market Size in France, in USD million (2020-2034)
• Table 47 Total Acute Ischemic Stroke Market Size in Italy, in USD million (2020-2034)
• Table 48 Total Acute Ischemic Stroke Market Size in Spain, in USD million (2020-2034)
• Table 49 Total Acute Ischemic Stroke Market Size in The UK, in USD million (2020-2034)
• Table 50 Total Acute Ischemic Stroke Market Size in EU4 and the UK, in USD million (2020-2034)
• Table 51 Acute Ischemic Stroke Market Size by Therapies in Germany, USD million (2020-2034)
• Table 52 Acute Ischemic Stroke Market Size by Therapies in France, USD million (2020-2034)
• Table 53 Acute Ischemic Stroke Market Size by Therapies in Italy, USD million (2020-2034)
• Table 54 Acute Ischemic Stroke Market Size by Therapies in Spain, USD million (2020-2034)
• Table 55 Acute Ischemic Stroke Market Size by Therapies in the UK, USD million (2020-2034)
• Table 56 Acute Ischemic Stroke Market Size by Therapies in EU4 and the UK, USD million (2020-2034)
• Table 57 Total Acute Ischemic Stroke Market Size in Japan, in USD million (2020-2034)
• Table 58 Acute Ischemic Stroke Market Size by Therapies in Japan, USD million (2020-2034)

List of Figures

• Figure 1 Total Incident Cases of Acute Ischemic Stroke In the 7MM (2020-2034)
• Figure 2 Total Diagnosed Incident Cases of Acute Ischemic Stroke In the 7MM (2020-2034)
• Figure 3 Total Diagnosed Incident Cases of Acute Ischemic Stroke in the US (2020-2034)
• Figure 4 Age-specific cases of Acute Ischemic Stroke in the US (2020-2034)
• Figure 5 Gender-specific Cases of Acute Ischemic Stroke in the US (2020-2034)
• Figure 6 Type-specific cases of Acute Ischemic Stroke in the US (2020-2034)
• Figure 7 Total Diagnosed Incident Cases of Acute Ischemic Stroke in Germany (2020-2034)
• Figure 8 Total Diagnosed Incident Cases of Acute Ischemic Stroke in France (2020-2034)
• Figure 9 Total Diagnosed Incident Cases of Acute Ischemic Stroke in Italy (2020-2034)
• Figure 10 Total Diagnosed Incident Cases of Acute Ischemic Stroke in Spain (2020-2034)
• Figure 11 Total Diagnosed Incident Cases of Acute Ischemic Stroke in the UK (2020-2034)
• Figure 12 Total Diagnosed Incident Cases of Acute Ischemic Stroke in EU4 and the UK (2020-2034)
• Figure 13 Age-specific cases of Acute Ischemic Stroke in Germany (2020-2034)
• Figure 14 Age-specific cases of Acute Ischemic Stroke in France (2020-2034)
• Figure 15 Age-specific cases of Acute Ischemic Stroke in Italy (2020-2034)
• Figure 16 Age-specific cases of Acute Ischemic Stroke in Spain (2020-2034)
• Figure 17 Age-specific cases of Acute Ischemic Stroke in the UK (2020-2034)
• Figure 18 Age-specific cases of Acute Ischemic Stroke in EU4 and the UK (2020-2034)
• Figure 19 Gender-specific Cases of Acute Ischemic Stroke in Germany (2020-2034)
• Figure 20 Gender-specific Cases of Acute Ischemic Stroke in France (2020-2034)
• Figure 21 Gender-specific Cases of Acute Ischemic Stroke in Italy (2020-2034)
• Figure 22 Gender-specific Cases of Acute Ischemic Stroke in Spain (2020-2034)
• Figure 23 Gender-specific Cases of Acute Ischemic Stroke in the UK (2020-2034)
• Figure 24 Gender-specific Cases of Acute Ischemic Stroke in EU4 and the UK (2020-2034)
• Figure 25 Type-specific cases of Acute Ischemic Stroke in Germany (2020-2034)
• Figure 26 Type-specific cases of Acute Ischemic Stroke in France (2020-2034)
• Figure 27 Type-specific cases of Acute Ischemic Stroke in Italy (2020-2034)
• Figure 28 Type-specific cases of Acute Ischemic Stroke in Spain (2020-2034)
• Figure 29 Type-specific cases of Acute Ischemic Stroke in the UK (2020-2034)
• Figure 30 Type-specific cases of Acute Ischemic Stroke in EU4 and the UK (2020-2034)
• Figure 31 Total Diagnosed Incident Cases of Acute Ischemic Stroke in Japan (2020-2034)
• Figure 32 Age-specific cases of Acute Ischemic Stroke in Japan (2020-2034)
• Figure 33 Gender-specific Cases of Acute Ischemic Stroke in Japan (2020-2034)
• Figure 34 Type-specific cases of Acute Ischemic Stroke in Japan (2020-2034)
• Figure 35 Patient Journey
• Figure 36 Total Acute Ischemic Stroke Market Size in the 7MM, in USD million (2020-2034)
• Figure 37 Acute Ischemic Stroke Market Size by Therapies in the 7MM, USD million (2020-2034)
• Figure 38 Total Acute Ischemic Stroke Market Size in the US, in USD million (2020-2034)
• Figure 39 Acute Ischemic Stroke Market Size by Therapies in the US, USD million (2020-2034)
• Figure 40 Total Acute Ischemic Stroke Market Size in Germany, in USD million (2020-2034)
• Figure 41 Total Acute Ischemic Stroke Market Size in France, in USD million (2020-2034)
• Figure 42 Total Acute Ischemic Stroke Market Size in Italy, in USD million (2020-2034)
• Figure 43 Total Acute Ischemic Stroke Market Size in Spain, in USD million (2020-2034)
• Figure 44 Total Acute Ischemic Stroke Market Size in The UK, in USD million (2020-2034)
• Figure 45 Total Acute Ischemic Stroke Market Size in EU4 and the UK, in USD million (2020-2034)
• Figure 46 Acute Ischemic Stroke Market Size by Therapies in Germany, USD million (2020-2034)
• Figure 47 Acute Ischemic Stroke Market Size by Therapies in France, USD million (2020-2034)
• Figure 48 Acute Ischemic Stroke Market Size by Therapies in Italy, USD million (2020-2034)
• Figure 49 Acute Ischemic Stroke Market Size by Therapies in Spain, USD million (2020-2034)
• Figure 50 Acute Ischemic Stroke Market Size by Therapies in the UK, USD million (2020-2034)
• Figure 51 Acute Ischemic Stroke Market Size by Therapies in EU4 and the UK, USD million (2020-2034)
• Figure 52 Total Acute Ischemic Stroke Market Size in Japan, in USD million (2020-2034)
• Figure 53 Acute Ischemic Stroke Market Size by Therapies in Japan, USD million (2020-2034)
• Figure 54 Unmet Needs
• Figure 55 Reimbursement Process in the United States
• Figure 56 Reimbursement Process in Germany
• Figure 57 Reimbursement Process in France
• Figure 58 Reimbursement process in Italy
• Figure 59 Reimbursement Process in Spain
• Figure 60 Reimbursement Process in the United Kingdom
• Figure 61 Reimbursement Process in Japan

Key Highlights:

• In 2023, the Acute ischemic stroke market size was highest in the US among the 7MM, accounting for approximately USD 801 million which is further expected to increase by 2034 at a CAGR of 11%.
• In 2023, the diagnosed incidence of Acute Ischemic Stroke was highest in the US among the 7MM, accounting for nearly 754 thousand cases which is further expected to increase by 2034.
• In the United States, in 2023, ~376 thousand males and ~378 thousand females were affected with acute ischemic stroke.
• The Acute ischemic stroke market is driven by advancements in thrombectomy, increasing incidence due to lifestyle factors, and funding for stroke care. Barriers include limited treatment windows, high costs, and a lack of awareness. Unmet needs encompass improved diagnostics, extended treatment windows, neuroprotection, and better post-stroke rehabilitation.
• The current Acute ischemic stroke treatment market comprises antiplatelets, anticoagulants, tissue plasminogen activator (tPA), edaravone, and lipid-lowering agents. However, this market faces substantial challenges, such as a narrow treatment window, delayed diagnosis, limited access to specialized care, safety concerns, high costs, and regulatory obstacles. These issues highlight the critical need for improved early detection, public education, and more effective, accessible therapies.
• Glenzocimab's ACTISAVE trial, a Phase II/III efficacy study, recruited participants from seven European countries, Israel, the UK, and the USA. The results from the 400-patient ACTISAVE study were presented at the European Stroke Organization Conference (ESOC) in May 2024.
• The Acute ischemic stroke market size in Japan was USD 122 million in 2023, which is expected to rise by 2034.

DelveInsight's "Acute Ischemic Stroke Market Insights, Epidemiology, and Market Forecast - 2034" report delivers an in-depth understanding of the acute ischemic stroke, historical and forecasted epidemiology as well as the Acute Ischemic Stroke market trends in the United States, EU4 and the UK (Germany, France, Italy, Spain), the United Kingdom, and Japan.

The Acute Ischemic Stroke market report provides current treatment practices, emerging drugs, and market share of the individual therapies, current and forecasted 7MM Acute Ischemic Stroke market size from 2020 to 2034. The report also covers current Acute Ischemic Stroke treatment practice, market drivers, market barriers, SWOT analysis, reimbursement and market access, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.

Geography Covered:

• The United States
• EU4 (Germany, France, Italy, and Spain) and the United Kingdom
• Japan

Study Period: 2020-2034

Acute Ischemic Stroke Treatment Market

Acute Ischemic Stroke Overview

Acute Ischemic Stroke (AIS) occurs when a blood vessel supplying the brain is blocked, leading to reduced blood flow and oxygen deprivation. This blockage is typically caused by a blood clot, often forming in narrowed arteries (atherosclerosis) or traveling from the heart or elsewhere in the body. The resulting lack of oxygen and nutrients causes brain cells to die, resulting in neurological deficits such as paralysis, speech difficulties, and cognitive impairments. Immediate medical intervention, such as intravenous thrombolysis or mechanical thrombectomy, is crucial to restore blood flow and minimize brain damage. Risk factors for AIS include hypertension, diabetes, smoking, and obesity.

Acute Ischemic Stroke Diagnosis

The diagnosis of acute Ischemic Stroke involves a combination of clinical evaluation and imaging techniques. Patients often present with sudden neurological symptoms such as weakness, speech difficulties, or visual disturbances. Rapid assessment using the NIH Stroke Scale (NIHSS) helps determine stroke severity. Computed Tomography (CT) scans or Magnetic Resonance Imaging (MRI) are crucial for differentiating Ischemic Stroke from hemorrhagic stroke, as well as identifying the affected brain region and the presence of ischemia. Additionally, vascular imaging techniques like CT angiography or MR angiography are used to assess blood vessel blockages, guiding appropriate treatment strategies.

Acute Ischemic Stroke Treatment

Treatment of acute Ischemic Stroke (AIS) focuses on rapidly restoring blood flow to the affected area of the brain. The primary treatments are thrombolytic therapy with tissue plasminogen activator (tPA), which dissolves blood clots and is most effective when administered within 4.5 hours of symptom onset. Mechanical thrombectomy, a procedure that physically removes clots using specialized devices, is another option for eligible patients, particularly when performed within 24 hours of stroke onset. Early diagnosis and prompt treatment are crucial in minimizing brain damage and improving recovery outcomes. Additional treatments may include antiplatelet agents, anticoagulants, and supportive care in a stroke unit.

Acute Ischemic Stroke Epidemiology

As the Acute ischemic stroke market is derived using a patient-based model, the Acute Ischemic Stroke epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by Diagnosed Incident Cases of Acute Ischemic Stroke, Gender-specific Cases of Acute Ischemic Stroke, Age-specific Cases of Acute Ischemic Stroke, and Type-specific Cases of Acute Ischemic Stroke in the 7MM covering, the United States, EU4 countries (Germany, France, Italy, and Spain), the United Kingdom, and Japan from 2020 to 2034.

• In the assessment done by DelveInsight, the estimated total diagnosed incident cases of Acute Ischemic Stroke in the 7MM were nearly 1,640 thousand in 2023.
• The highest total diagnosed incident cases of Acute Ischemic Stroke were accounted by the US in 2023 (754 thousand), which are expected to show a rise in the future.
• Among the European countries, Germany had the highest diagnosed incident cases of Acute Ischemic Stroke with ~265 thousand cases in 2023. On the other hand, Spain had the lowest incident population (60 thousand cases).
• Japan had nearly 236 thousand total diagnosed incident cases of Acute Ischemic Stroke in 2023, accounting for approximately 14% in 7MM.
• The incident cases of acute ischemic stroke (AIS) in Japan in 2023 were categorized by type, including large-artery atherosclerosis, small artery occlusions, cardioembolism, and other/undetermined causes. Among these, cardioembolism had the highest incidence, with around 77 thousand cases reported.
• The cases were divided by age into four groups: 0-64 years, 65-74 years, 75-84 years, and 85+ years. In the EU4 and the UK, the highest number of cases in 2023 occurred in the 75-84 years age group, with approximately 200,000 cases reported.

Recent Developments in Acute Ischemic Stroke Clinical Trials

• On October 30, 2024, Prolong Pharmaceuticals, LLC, a clinical-stage biopharmaceutical company, announced that its investigational therapy, PP-007 (PEGylated carboxyhemoglobin, bovine), has been granted Fast Track designation by the FDA for treating acute ischemic stroke (AIS). PP-007 is currently undergoing safety and efficacy evaluation in the ongoing U.S.-based clinical trial, HEMERA-1.
• On October 22, 2024, Remedy Pharmaceuticals, a leader in stroke drug development, announced that the FDA's Office of Orphan Products Division (OOPD) has granted Orphan Drug Designation for CIRARA to treat large territory acute ischemic stroke, including large hemispheric infarctions (LHI).

Acute Ischemic Stroke Drug Chapters

The drug chapter segment of the Acute Ischemic Stroke market report encloses a detailed analysis of Acute Ischemic Stroke off-label drugs and late-stage (Phase III and Phase II) pipeline drugs. It also helps to understand the Acute Ischemic Stroke clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.

Acute Ischemic Stroke Emerging Drugs

Glenzocimab (ACT017): Acticor Biotech

Glenzocimab (ACT017) is a humanized monoclonal antibody (mAb) fragment directed against a novel target of major interest, platelet glycoprotein VI (GPVI). It inhibits platelet binding to the thrombus without affecting physiological hemostasis, thereby limiting the bleeding risk, particularly in the brain. GPVI is expressed exclusively by platelets and their precursors, megakaryocytes. It is a key receptor on platelets for polymerized fibrin, fibrinogen, and collagen. GPVI interaction with its ligands triggers platelet activation, leading to aggregation, the recruitment of additional platelets, and promoting coagulation. GPVI blockade has demonstrated efficient antithrombotic potential in experimental thrombosis models without increasing bleeding.

Glenzocimab is in advanced clinical development for Acute Ischemic Stroke and myocardial infarction, with mixed results from ongoing trials.

LT3001: Lumosa Therapeutics

LT3001 is a novel small molecule for the treatment of acute ischemic stroke. It is a novel molecule composed of a synthetic peptide and a free radical scavenger and has demonstrated recanalization capabilities without the increased risk of hemorrhagic transformation. The peptide moiety is modified from the degradation products of fibrinogen, and it blocks the binding between platelet and fibrinogen, the two major components of thrombus. The small molecule portion is an antioxidant designed to limit oxidative stress and protect tissues from ischemia/reperfusion injury. Additionally, at the thrombosis site, it safely restores blood vessel patency by promoting the local endogenous fibrinolysis activity, enhancing plasminogen binding to the fibrin clot and facilitating the activation of plasminogen to plasmin while simultaneously protecting the tissues from free radicals and inflammation-mediated injury.

LT3001 has shown promising results in its Phase IIa trial, meeting its primary safety endpoint and demonstrating neurological improvement in Acute Ischemic Stroke patients.

Acute Ischemic Stroke Market Outlook

Acute Ischemic Stroke (AIS) is a critical medical condition caused by a sudden blockage in a blood vessel supplying the brain, leading to a loss of blood flow and oxygen to the affected brain region. Rapid treatment is essential to minimize brain damage and improve outcomes.

The primary treatment for AIS involves restoring blood flow to the brain as quickly as possible. The mainstay of pharmacological treatment is intravenous thrombolysis with tissue plasminogen activator (tPA), such as alteplase. tPA works by dissolving the blood clot blocking the artery and must be administered within 4.5 hours of stroke onset to be most effective. Beyond this time frame, the risks of bleeding complications increase significantly.

For patients with large artery occlusions, mechanical thrombectomy has emerged as a highly effective treatment option. This minimally invasive procedure involves inserting a catheter through the blood vessels to the site of the blockage, where a device like a stent retriever or aspiration catheter removes or breaks up the clot. Mechanical thrombectomy can be performed within 24 hours of symptom onset and is often used in conjunction with tPA.

Additional treatments for Acute ischemic stroke may include antiplatelet agents, anticoagulants, and supportive care to manage blood pressure, blood sugar, and other vital parameters. Post-stroke rehabilitation, involving physical, occupational, and speech therapies, is crucial for maximizing recovery and improving the quality of life for stroke survivors.

• The Acute ischemic stroke market size in the 7MM was ~USD 1,296 million in 2023, which is further anticipated to increase during the forecast period.
• The United States accounted for the highest Acute ischemic stroke market size approximately 62% of the total Acute ischemic stroke market size in 7MM in 2023, in comparison to the other major markets i.e., EU4 countries (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
• Among the EU countries, Germany had the highest Acute ischemic stroke market size with nearly USD 150 million in 2023, while Spain had the lowest Acute ischemic stroke market size with USD ~34 million in 2023.
• The Acute ischemic stroke market size in Japan was estimated to be about USD 122 million in 2023.
• With the expected launch of upcoming Acute ischemic stroke therapies, such as Glenzocimab (ACT017), LT3001, and DM199, among others, the total Acute ischemic stroke market size is expected to show change in the upcoming years.

Acute Ischemic Stroke Drugs Uptake

This section focuses on the uptake rate of potential Acute ischemic stroke drugs expected to launch in the market during 2020-2034. For example, DM199 in the US is expected to be launched by 2025 with a peak share of 2.88%. DM199 is anticipated to take 7 years to peak with a medium uptake.

Acute Ischemic Stroke Pipeline Development Activities

The Acute ischemic stroke market report provides insights into different Acute Ischemic Stroke clinical trials within Phase III, Phase II, and Phase I stage. It also analyzes key players involved in developing targeted therapeutics.

Pipeline Development Activities

The Acute ischemic stroke market report covers information on collaborations, acquisitions and mergers, licensing, and patent details for Acute Ischemic Stroke emerging therapies.

Acute ischemic stroke KOL Views

To keep up with current Acute ischemic stroke market trends, we take KOLs and SMEs' opinions working in the domain through primary research to fill the data gaps and validate the secondary research. Industry Experts were contacted for insights on Acute Ischemic Stroke evolving treatment landscape, patient reliance on conventional therapies, patient therapy switching acceptability, and drug uptake along with challenges related to accessibility, including KOL from Medical University of South Carolina, US; Sapienza University of Rome, Italy; University of Duisburg-Essen, Germany; Hopital Lariboisiere, France; Vall d'Hebron University Hospital, Spain; University College London Hospitals, UK and Kyoto University Hospital, Japan; and others.

Delveinsight's analysts connected with 50+ KOLs to gather insights; however, interviews were conducted with 15+ KOLs in the 7MM. Their opinion helps understand and validate current and emerging therapies, treatment patterns, or Acute Ischemic Stroke market trends. This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the market and the unmet needs.

Qualitative Analysis

We perform Qualitative and market Intelligence analysis using various approaches, such as SWOT and Conjoint Analysis. In the SWOT analysis, strengths, weaknesses, opportunities, and threats in terms of disease diagnosis, patient awareness, patient burden, competitive landscape, cost-effectiveness, and geographical accessibility of therapies are provided. These pointers are based on the Analyst's discretion and assessment of the patient burden, cost analysis, and existing and evolving treatment landscape.

Conjoint Analysis analyzes multiple approved and emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry. Scoring is given based on these parameters to analyze the effectiveness of therapy.

Further, the therapies' safety is evaluated wherein the acceptability, tolerability, and adverse events are majorly observed, and it sets a clear understanding of the side effects posed by the drug in the trials. In addition, the scoring is also based on the route of administration, order of entry and designation, probability of success, and the addressable patient pool for each therapy. According to these parameters, the final weightage score and the ranking of the emerging therapies are decided.

Acute ischemic stroke Market Access and Reimbursement

The high cost of therapies for the treatment is a major factor restraining the growth of the global drug market. Because of the high cost, the economic burden is increasing, leading the patient to escape from proper treatment.

The Acute ischemic stroke market report further provides detailed insights on the country-wise accessibility and reimbursement scenarios, cost-effectiveness scenario of approved therapies, programs making accessibility easier and out-of-pocket costs more affordable, insights on patients insured under federal or state government prescription drug programs, etc.

Scope of the Acute Ischemic Stroke Market Report

• The Acute ischemic stroke market report covers a segment of key events, an executive summary, descriptive overview of acute ischemic stroke, explaining its causes, signs and symptoms, and currently available therapies.
• Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of diagnosis rate, disease progression, and treatment guidelines.
• Additionally, an all-inclusive account of the current and emerging therapies and the elaborative profiles of late-stage and prominent therapies will impact the current treatment landscape.
• A detailed review of the Acute Ischemic Stroke market, historical and forecasted market size, market share by therapies, detailed assumptions, and rationale behind the approach is included in the report covering the 7MM drug outreach.
• The Acute ischemic stroke market report provides an edge while developing business strategies, by understanding trends, through SWOT analysis and expert insights/KOL views, patient journey, and treatment preferences that help shape and drive the 7MM Acute Ischemic Stroke market.

Acute Ischemic Stroke Market Report Insights

• Acute Ischemic Stroke Patient Population
• Acute Ischemic Stroke Therapeutic Approaches
• Acute Ischemic Stroke Pipeline Analysis
• Acute Ischemic Stroke Market Size
• Acute ischemic stroke Market Trends
• Existing and Future Acute ischemic stroke Market Opportunity

Acute Ischemic Stroke Market Report Key Strengths

• 11 years Forecast
• The 7MM Coverage
• Acute Ischemic Stroke Epidemiology Segmentation
• Key Cross Competition
• Conjoint Analysis
• Acute Ischemic Stroke Drugs Uptake
• Key Acute Ischemic Stroke Market Forecast Assumptions

Acute Ischemic Stroke Market Report Assessment

• Current Acute Ischemic Stroke Treatment Practices
• Acute Ischemic Stroke Unmet Needs
• Acute Ischemic Stroke Pipeline Product Profiles
• Acute Ischemic Stroke Market Attractiveness
• Qualitative Analysis (SWOT and Conjoint Analysis)
• Acute Ischemic Stroke Market Drivers
• Acute Ischemic Stroke Market Barriers

Key Questions Answered In The Acute ischemic stroke Market Report

Acute Ischemic Stroke Market Insights

• What was the Acute Ischemic Stroke market share (%) distribution in 2020 and how it would look like in 2034?
• What would be the Acute Ischemic Stroke market size as well as market size by therapies across the 7MM during the forecast period (2024-2034)?
• What are the key findings pertaining to the market across the 7MM and which country will have the largest Acute Ischemic Stroke market size during the forecast period (2024-2034)?
• At what CAGR, the Acute Ischemic Stroke market is expected to grow at the 7MM level during the forecast period (2024-2034)?
• What would be the Acute Ischemic Stroke market outlook across the 7MM during the forecast period (2024-2034)?
• What would be the Acute Ischemic Stroke market growth till 2034 and what will be the resultant market size in the year 2034?
• How would the market drivers, barriers, and future opportunities affect the Acute ischemic stroke market dynamics and subsequent analysis of the associated trends?

Acute Ischemic Stroke Epidemiology Insights

• What is the disease risk, burden, and unmet needs of acute ischemic stroke?
• What is the historical Acute Ischemic Stroke patient population in the United States, EU5 (Germany, France, Italy, Spain, and the UK), and Japan?
• What would be the forecasted patient population of Acute Ischemic Stroke at the 7MM level?
• What will be the growth opportunities across the 7MM with respect to the patient population pertaining to acute ischemic stroke?
• Out of the above-mentioned countries, which country would have the highest incident population of Acute Ischemic Stroke during the forecast period (2024-2034)?
• At what CAGR the population is expected to grow across the 7MM during the forecast period (2024-2034)?

Current Acute Ischemic Stroke Treatment Scenario, Marketed Drugs, and Emerging Therapies

• What are the current options for the treatment of Acute Ischemic Stroke along with the approved therapy?
• What are the current treatment guidelines for the treatment of Acute Ischemic Stroke in the US, Europe, And Japan?
• What are the Acute Ischemic Stroke marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety, and efficacy, etc.?
• How many companies are developing therapies for the treatment of acute ischemic stroke?
• How many emerging therapies are in the mid-stage and late stages of development for the treatment of acute ischemic stroke?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Acute Ischemic Stroke therapies?
• What are the recent therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Acute Ischemic Stroke and their status?
• What are the key designations that have been granted for the emerging therapies for acute ischemic stroke?
• What are the 7MM historical and forecasted Acute ischemic stroke market?

Reasons to Buy Acute Ischemic Stroke Market Report

• The Acute ischemic stroke market report will help in developing business strategies by understanding the latest trends and changing treatment dynamics driving the Acute Ischemic Stroke Market.
• Insights on patient burden/disease incidence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• To understand the existing Acute ischemic stroke market opportunity in varying geographies and the growth potential over the coming years.
• Distribution of historical and current patient share based on real-world prescription data along with reported sales of approved products in the US, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
• Identification of strong upcoming Acute ischemic stroke companies in the market will help in devising strategies that will help in getting ahead of competitors.
• Detailed analysis and potential of current and emerging Acute ischemic stroke therapies under the conjoint analysis section to provide visibility around leading emerging drugs.
• Highlights of Access and Reimbursement policies of approved therapies, barriers to accessibility of off-label expensive therapies, and patient assistance programs.
• To understand the perspective of Key Opinion Leaders around the accessibility, acceptability, and compliance-related challenges of existing treatment to overcome barriers in future.
• Detailed insights on the unmet need of the existing Acute ischemic stroke market so that the upcoming players can strengthen their development and launch strategy.

Frequently Asked Questions:

1. What is the forecast period covered in the report?

The Acute Ischemic Stroke Epidemiology and Market Insight report for the 7MM covers the forecast period from 2024 to 2034, providing a projection of market dynamics and trends during this timeframe.

2. Who are the key players in the Acute Ischemic Stroke market?

The Acute Ischemic Stroke market is quite robust. The major layers are Acticor Biotech, Lumosa Therapeutics, DiaMedica Therapeutics Inc., and others which are currently developing drugs for the treatment of acute ischemic stroke.

3. How is the market size estimated in the forecast report?

The market size is estimated through data analysis, statistical modeling, and expert opinions. It may consider factors such as incident cases, treatment costs, revenue generated, and market trends.

4. What is the key driver of the Acute Ischemic Stroke market?

The increase in diagnosed incident cases of Acute Ischemic Stroke and the launch of emerging therapies are attributed to be the key drivers for increasing the Acute Ischemic Stroke market.

5. What is the expected impact of emerging therapies or advancements in Acute Ischemic Stroke treatment on the market?

Introducing new therapies, advancements in diagnostic techniques, and innovations in treatment approaches can significantly impact the Acute Ischemic Stroke treatment market. Market forecast reports may provide analysis and predictions regarding the potential impact of these developments.

6. Does the report provide insights into the competitive landscape of the market?

The market forecast report may include information on the competitive landscape, profiling key market players, their product offerings, partnerships, and strategies, and helping stakeholders understand the competitive dynamics of the Acute Ischemic Stroke market.

Table of Contents

1 Key Insights

2 Report Introduction

3 Acute ischemic stroke Market Overview at a Glance

• 3.1 Market Share (%) Distribution of Acute ischemic stroke by Therapies in 2020
• 3.2 Market Share (%) Distribution of Acute ischemic stroke by Therapies in 2034

4 Epidemiology and Market Forecast Methodology

5 Key Events

6 Executive Summary

7 Disease Background and Overview

• 7.1 Introduction
• 7.2 Signs and Symptoms
• 7.3 Stages and Clinical presentation of Acute ischemic stroke
• 7.4 Causes
• 7.5 Pathogenesis
• 7.6 Acute ischemic stroke Diagnosis
  • 7.6.1 Diagnostic Algorithm
  • 7.6.2 Diagnostic Approach
  • 7.6.3 Diagnostic Recommendations
• 7.7 Differential Diagnosis
• 7.8 Treatment and Management
  • 7.8.1 General Management
  • 7.8.2 Surgical Management
  • 7.8.3 Treatment Algorithm
  • 7.8.4 Treatment Recommendations

8 Epidemiology and Patient Population of Acute ischemic stroke

• 8.1 Key Findings: Epidemiology
• 8.2 Assumptions and Rationale: 7MM
• 8.3 Total Incident Cases of Acute ischemic stroke in the 7MM
• 8.4 Total Diagnosed Incident Cases of Acute ischemic stroke in the 7MM
• 8.5 The United States
  • 8.5.1 Total Diagnosed Incident Cases of Acute ischemic stroke in the United States
  • 8.5.2 Age-specific cases of Acute Ischemic Stroke in the United States
  • 8.5.3 Gender-specific Cases of Acute ischemic stroke in the United States
  • 8.5.4 Type-specific cases of Acute Ischemic Stroke in the United States
• 8.6 EU4 and the UK
  • 8.6.1 Germany
    • 8.6.1.1 Total Diagnosed Incident Cases of Acute ischemic stroke
    • 8.6.1.2 Age-specific cases of Acute Ischemic Stroke
    • 8.6.1.3 Gender-specific Cases of Acute ischemic stroke
    • 8.6.1.4 Type-specific cases of Acute Ischemic Stroke
  • 8.6.2 France
    • 8.6.2.1 Total Diagnosed Incident Cases of Acute ischemic stroke
    • 8.6.2.2 Age-specific cases of Acute Ischemic Stroke
    • 8.6.2.3 Gender-specific Cases of Acute ischemic stroke
    • 8.6.2.4 Type-specific cases of Acute Ischemic Stroke
  • 8.6.3 Italy
    • 8.6.3.1 Total Diagnosed Incident Cases of Acute ischemic stroke
    • 8.6.3.2 Age-specific cases of Acute Ischemic Stroke
    • 8.6.3.3 Gender-specific Cases of Acute ischemic stroke
    • 8.6.3.4 Type-specific cases of Acute Ischemic Stroke
  • 8.6.4 Spain
    • 8.6.4.1 Total Diagnosed Incident Cases of Acute ischemic stroke in Japan
    • 8.6.4.2 Age-specific cases of Acute Ischemic Stroke
    • 8.6.4.3 Gender-specific Cases of Acute ischemic stroke
    • 8.6.4.4 Type-specific cases of Acute Ischemic Stroke
  • 8.6.5 The United Kingdom
    • 8.6.5.1 Total Diagnosed Incident Cases of Acute ischemic stroke
    • 8.6.5.2 Age-specific cases of Acute Ischemic Stroke
    • 8.6.5.3 Gender-specific Cases of Acute ischemic stroke
    • 8.6.5.4 Type-specific cases of Acute Ischemic Stroke
• 8.7 Japan
  • 8.7.1 Total Diagnosed Incident Cases of Acute ischemic stroke
  • 8.7.2 Age-specific cases of Acute Ischemic Stroke in Japan
  • 8.7.3 Gender-specific Cases of Acute ischemic stroke in Japan
  • 8.7.4 Type-specific cases of Acute Ischemic Stroke in Japan

9 Acute ischemic stroke Patient Journey

10 Acute ischemic stroke Marketed Drug

• 10.1 BRILINTA (ticagrelor): AstraZeneca
  • 10.1.1 Product Description
  • 10.1.2 Regulatory milestone
  • 10.1.3 Other Developmental Activities
  • 10.1.4 Clinical Trials Information
  • 10.1.5 Safety and Efficacy
  • 10.1.6 Analysts' Views

11. Emerging Drugs

• 11.1 Key Cross Competition
• 11.2 Glenzocimab (ACT017): Acticor Biotech
  • 11.2.1 Product Description
  • 11.2.2 Other Developmental Activities
  • 11.2.3 Clinical Trials Information
  • 11.2.4 Safety and Efficacy
  • 11.2.5 Analysts' Views
• 11.3 LT3001: Lumosa Therapeutics
  • 11.3.1 Product Description
  • 11.3.2 Other Developmental Activities
  • 11.3.3 Clinical Trials Information
  • 11.3.4 Safety and Efficacy
  • 11.3.5 Analysts' Views
• 11.4 DM199: DiaMedica Therapeutics
  • 11.4.1 Product Description
  • 11.4.2 Other Developmental Activities
  • 11.4.3 Clinical Trials Information
  • 11.4.4 Safety and Efficacy
  • 11.4.5 Analysts' Views

12 Acute ischemic stroke Market: 7 Major Market Analysis

• 12.1 Key Findings
• 12.2 Key Market Forecast Assumptions
• 12.3 Acute ischemic stroke Market Outlook
• 12.4 Total Market Size of Acute ischemic stroke in the 7MM
• 12.5 Market Size of Acute ischemic stroke by Therapies in the 7MM
• 12.6 The United States
  • 12.6.1 Total Market Size of Acute ischemic stroke
  • 12.6.2 Market Size of Acute ischemic stroke by Therapies
• 12.7 EU4 and the UK
  • 12.7.1 Germany
    • 12.7.1.1 Total Market Size of Acute ischemic stroke
    • 12.7.1.2 Market Size of Acute ischemic stroke by Therapies
  • 12.7.2 France
    • 12.7.2.1 Total Market Size of Acute ischemic stroke
    • 12.7.2.2 Market Size of Acute ischemic stroke by Therapies
  • 12.7.3 Italy
    • 12.7.3.1 Total Market Size of Acute ischemic stroke
    • 12.7.3.2 Market Size of Acute ischemic stroke by Therapies
  • 12.7.4 Spain
    • 12.7.4.1 Total Market Size of Acute ischemic stroke
    • 12.7.4.2 Market Size of Acute ischemic stroke by Therapies
  • 12.7.5 The United Kingdom
    • 12.7.5.1 Total Market Size of Acute ischemic stroke
    • 12.7.5.2 Market Size of Acute ischemic stroke by Therapies
• 12.8 Japan
  • 12.8.1 Total Market Size of Acute ischemic stroke
  • 12.8.2 Market Size of Acute ischemic stroke by Therapies

13 Key Opinion Leaders' Views

14 Acute ischemic stroke SWOT Analysis

15 Acute ischemic stroke Unmet Needs

16 Acute ischemic stroke Market Access and Reimbursement

• 16.1 The United States
  • 16.1.1 Centre for Medicare and Medicaid Services (CMS)
• 16.2 In EU4 and the UK
  • 16.2.1 Germany
  • 16.2.2 France
  • 16.2.3 Italy
  • 16.2.4 Spain
  • 16.2.5 The United Kingdom
• 16.3 Japan
  • 16.3.1 MHLW

17 Appendix

• 17.1 Bibliography
• 17.2 Acronyms and Abbreviations

18 Report Methodology

19 DelveInsight Capabilities

20 Disclaimer